NeuroTherapeutics Pharma, Inc. (NTP) is a biopharmaceutical company developing new therapies to treat pain, epilepsy, and other nervous system disorders. NTP is advancing compounds that act through a novel mechanism of action to create a new class of medicines with potential broad application across a range of neurological and neuropsychiatric conditions.
Adequate and safe control of pain and epilepsy represent significant unmet medical needs today. While currently available medications in these areas provide some benefit for some patients, much of the patient population with pain, epilepsy and related conditions contend with a combination of inadequate symptom relief and significant side effects caused by their treatment.
NTP is developing first-in-class therapeutics with the potential to change the standard of care for these patients. NTP’s novel compounds act through a previously unexplored mechanism of action unlike those of existing therapies. This approach has the potential to provide patients with a new way to treat neurological disorders and a way to improve upon both efficacy and safety.
NTP is led by a management team with significant drug development experience and is financially backed by a well respected group of venture capital investors. The company raised a $43 million Series B financing in May of 2010, which included participation from Fidelity Biosciences, MPM Capital, Novo Ventures, Pfizer, SR One and Thomas McNerney & Partners. The company is based in Chicago.
